CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 106 enrolled
Drug / intervention
Diagnostic MRI +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03585660
NCT03585660N/ACompleted
CompareCT.gov

MRI Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

University of Chicago·interventional·Posted Jul 13, 2018·Updated Sep 19, 2024

In Brief

A clinical study evaluating Diagnostic MRI, Diagnostic Prostate Biopsy, and 1 other intervention for Prostate Cancer. Completed, enrolled 106 participants across 1 site.

Detailed Summary

The purpose of the proposed research is to test and validate a Risk Map decision-support system (DSS) for prostate cancer Magnetic Resonance Imaging (MRI) interpretation and identification of clinically significant tumor site(s).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJul 13, 2018
Enrollment StartAug 28, 2018
Primary CompletionJun 9, 2023
Study CompletionNov 6, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 8.0 years ago

Interventions

Diagnostic MRIprocedure

Participants will be scanned using a standard clinical prostate MRI protocol.

Diagnostic Prostate Biopsyprocedure

Participants will undergo a prostate biopsy as their standard of care treatment. The provider performing biopsy will select areas to be biopsies as part of normal clinical judgment.

Risk Map DSS tooldevice

The Risk Map DSS tool will select up to 2 additional areas to be biopsied based on analysis of MRI images. The clinical provider will make final decision on areas to be biopsied.